The relationship between cerebrospinal fluid neurofilament light protein biomarker and cortical thinning across the spectrum of Alzheimer’s disease

Alzheimer’s disease (AD) is an age‐related neurodegenerative disease pathologically characterized by beta‐amyloid plaque accumulation and tau‐protein neurofibrillary tangles in the brain. Recent research has sought to identify additional potential biomarkers for earlier detection and treatment of the disease, including one such protein named cerebrospinal fluid neurofilament light protein (CSF NfL). Despite CSF NfL’s essential contributions to forming the neuronal cytoskeleton and supporting neuroaxonal function, the roles of CSF NfL in longitudinal AD progression and AD‐related neurodegeneration remain to be elucidated. This study examined the relationships between baseline CSF NfL levels and cortical gray matter atrophy along the spectrum of AD on a longitudinal scale over the span of two years.